UBX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 00:48):

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging...

Stats
今日成交量	27 694.00
平均成交量	90 258.00
市值	25.43M
EPS	$0 ( 2024-04-03 )
下一个收益日期	( $-0.570 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.560
ATR14	$0.00500 (0.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-26	Nguyen Alexander Hieu	Buy	30 000	Stock Option (Right to Buy)
2024-03-26	Nguyen Alexander Hieu	Buy	20 000	Common Stock, $0.0001 par value
2024-02-02	Ghosh Anirvan	Sell	680	Common Stock, $0.0001 par value
2024-01-30	Ghosh Anirvan	Sell	1 183	Common Stock, $0.0001 par value
2023-11-02	Ghosh Anirvan	Sell	589	Common Stock, $0.0001 par value

INSIDER POWER
55.05
Last 99 transactions
Buy: 2 792 498 \| Sell: 401 244

音量相关性

長: 0.06 (neutral)

短: 1.00 (very strong)

Signal:(50.941) Expect same movement, but be aware

UNITY Biotechnology Inc 相关性

10 最正相关
XLRN	0.938
BRACU	0.938
NVCN	0.934
LX	0.931
ATRS	0.924
SY	0.924
ATCX	0.923
PUCK	0.919
GXII	0.919
OVID	0.918

10 最负相关
NAKD	-0.928
AHPI	-0.923
AMGN	-0.908
PROC	-0.906
GRPH	-0.905
GRIN	-0.903
LCAP	-0.899
LAWS	-0.896
TRIT	-0.892
CYTO	-0.888

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

UNITY Biotechnology Inc 相关性 - 货币/商品

0.83
( strong )

0.80
( strong )

0.00
( neutral )

-0.75
( moderate negative )

-0.79
( moderate negative )

UNITY Biotechnology Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-1.18M (0.00 %)
EPS:	$-2.70

FY	2023
营收:	$0
毛利润:	$-1.18M (0.00 %)
EPS:	$-2.70

FY	2022
营收:	$236 000
毛利润:	$-1.94M (-823.73 %)
EPS:	$-6.08

FY	2021
营收:	$4 784.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.0109

Financial Reports:

No articles found.

UNITY Biotechnology Inc

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.